PMID- 24528218
OWN - NLM
STAT- MEDLINE
DCOM- 20150818
LR  - 20191210
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 55
IP  - 12
DP  - 2014 Dec
TI  - Human leukocyte antigen-DR expression on flow cytometry and tumor-associated 
      macrophages in diffuse large B-cell lymphoma treated by rituximab, 
      cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective 
      cohort study.
PG  - 2721-7
LID - 10.3109/10428194.2014.893311 [doi]
AB  - Loss of human leukocyte antigen (HLA)-DR expression may be related to a poor 
      prognosis of diffuse large B-cell lymphoma (DLBCL), and tumor-associated 
      macrophages (TAMs) may influence tumor progression. We retrospectively reviewed 
      36 patients with newly diagnosed DLBCL who received R-CHOP (rituximab, 
      cyclophosphamide, doxorubicin, vincristine and prednisone) therapy at Kanagawa 
      Cancer Center in Japan from 2004 to 2010. HLA-DR expression by lymphoma cells was 
      evaluated using flow cytometry, and TAMs in lymphoma tissue were detected by 
      immunohistochemistry for CD68 as a marker of macrophages and CD163 as a marker of 
      M2 TAMs. Three-year overall survival was, respectively, 100% versus 69.6% in the 
      HLA-DR "bright" and "not bright" groups (p = 0.012). Patients from the HLA-DR 
      "not bright" group with strong CD163 expression had a much worse prognosis than 
      other patients. The HLA-DR status shown by flow cytometry can be used to predict 
      the prognosis of patients with DLBCL receiving R-CHOP therapy and prognostic 
      accuracy can be increased by also assessing TAMs.
FAU - Yamamoto, Wataru
AU  - Yamamoto W
AD  - Department of Medical Oncology, Kanagawa Cancer Center , Yokohama , Japan.
FAU - Nakamura, Naoya
AU  - Nakamura N
FAU - Tomita, Naoto
AU  - Tomita N
FAU - Takeuchi, Kengo
AU  - Takeuchi K
FAU - Ishii, Yoshimi
AU  - Ishii Y
FAU - Takahashi, Hiroyuki
AU  - Takahashi H
FAU - Watanabe, Reina
AU  - Watanabe R
FAU - Takasaki, Hirotaka
AU  - Takasaki H
FAU - Motomura, Shigeki
AU  - Motomura S
FAU - Kobayashi, Shoichi
AU  - Kobayashi S
FAU - Yokose, Tomoyuki
AU  - Yokose T
FAU - Ishigatsubo, Yoshiaki
AU  - Ishigatsubo Y
FAU - Sakai, Rika
AU  - Sakai R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140319
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (R-CHOP protocol)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - HLA-DR Antigens/*immunology/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunophenotyping
MH  - Lymphoma, Large B-Cell, Diffuse/*drug 
      therapy/*immunology/metabolism/mortality/pathology
MH  - Macrophages/*immunology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phenotype
MH  - Prednisone/therapeutic use
MH  - Prognosis
MH  - Retrospective Studies
MH  - Rituximab
MH  - Treatment Outcome
MH  - Vincristine/therapeutic use
OTO - NOTNLM
OT  - HLA-DR
OT  - R-CHOP therapy
OT  - diffuse large B-cell lymphoma
OT  - flow cytometry
OT  - tumor-associated macrophage
EDAT- 2014/02/18 06:00
MHDA- 2015/08/19 06:00
CRDT- 2014/02/18 06:00
PHST- 2014/02/18 06:00 [entrez]
PHST- 2014/02/18 06:00 [pubmed]
PHST- 2015/08/19 06:00 [medline]
AID - 10.3109/10428194.2014.893311 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2014 Dec;55(12):2721-7. doi: 10.3109/10428194.2014.893311. Epub 
      2014 Mar 19.